LncRNA NEAT1 promotes IL-6 secretion in monocyte-derived dendritic cells via sponging miR-365a-3p in systemic lupus erythematosus

References

• Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–12. doi:10.1136/ard-2022-223035
   PubMed Web of Science ®Google Scholar
• Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology. 2017;56(11):1945–1961. doi:10.1093/rheumatology/kex260
   PubMed Web of Science ®Google Scholar
• Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early b-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4(3):579–587. doi:10.2215/CJN.04030808
   PubMed Web of Science ®Google Scholar
• Liossis S-N, Staveri C. B cell-based treatments in SLE: past experience and current directions. Curr Rheumatol Rep. 2017;19(12):78. doi: 10.1007/s11926-017-0707-z
   PubMed Web of Science ®Google Scholar
• Herrada AA, Escobedo N, Iruretagoyena M, et al. Innate immune cells’ contribution to systemic lupus erythematosus. Front Immunol. 2019;10:772. doi: 10.3389/fimmu.2019.00772
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka A, Pascual V, et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19(1):41–52. doi:10.1016/j.cytogfr.2007.10.004
   PubMed Web of Science ®Google Scholar
• Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell–induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med. 2003;9(12):1484–1490. doi:10.1038/nm960
   PubMed Web of Science ®Google Scholar
• Bell GM, Anderson AE, Diboll J, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017;76(1):227–234. doi:10.1136/annrheumdis-2015-208456
   PubMed Web of Science ®Google Scholar
• Phillips BE, Garciafigueroa Y, Engman C, et al. Tolerogenic dendritic cells and T-Regulatory cells at the clinical trials crossroad for the treatment of autoimmune disease; emphasis on type 1 diabetes therapy. Front Immunol. 2019;10:148. doi: 10.3389/fimmu.2019.00148
   PubMed Web of Science ®Google Scholar
• Ding D, Mehta H, McCune WJ, et al. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol. 2006;177(9):5878–5889. doi:10.4049/jimmunol.177.9.5878
   PubMed Web of Science ®Google Scholar
• Wang Y, Liang J, Qin H, et al. Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE. Arthritis Res Ther. 2016;18(1):263. doi:10.1186/s13075-016-1158-z
   PubMedGoogle Scholar
• Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81(1):145–166. doi: 10.1146/annurev-biochem-051410-092902
   PubMed Web of Science ®Google Scholar
• Niu L, Lou F, Sun Y, et al. A micropeptide encoded by lncRNA MIR155HG suppresses autoimmune inflammation via modulating antigen presentation. Sci Adv. 2020;6(21):eaaz2059. doi:10.1126/sciadv.aaz2059
   PubMed Web of Science ®Google Scholar
• Wang P, Xue Y, Han Y, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014;344(6181):310–313. doi:10.1126/science.1251456
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang X, Chen K, et al. CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis. Immunity. 2019;50(3):600–615.e15. doi:10.1016/j.immuni.2019.01.021
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011;146(3):353–358. doi:10.1016/j.cell.2011.07.014
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen S, Chen S, et al. Long noncoding RNA expression profile and association with SLEDAI score in monocyte-derived dendritic cells from patients with systematic lupus erythematosus. Arthritis Res Ther. 2018;20(1):138. doi:10.1186/s13075-018-1640-x
   PubMedGoogle Scholar
• Li S, Li J, Chen C, et al. Pan-cancer analysis of long non-coding RNA NEAT1 in various cancers. Genes Dis. 2018;5(1):27–35. doi:10.1016/j.gendis.2017.11.003
   PubMed Web of Science ®Google Scholar
• Zhang P, Cao L, Zhou R, et al. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10(1):1495. doi:10.1038/s41467-019-09482-6
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Scandella E, Allmen E, et al. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods. 2004;287(1–2):109–124. doi:10.1016/j.jim.2004.01.010
   PubMed Web of Science ®Google Scholar
• Martin H, Laborel-Préneron E, Fraysse F, et al. Aquaphilus dolomiae extract counteracts the effects of cutaneous S. aureus secretome isolated from atopic children on CD4 + T cell activation. Pharm Biol. 2016;54(11):2782–2785. doi:10.3109/13880209.2016.1173069
   PubMed Web of Science ®Google Scholar
• Shaban A, Leira EC. Neurological complications in patients with systemic lupus erythematosus. Curr Neurol Neurosci Rep. 2019;19(12):97. doi: 10.1007/s11910-019-1012-1
   PubMed Web of Science ®Google Scholar
• Mohamed A, Chen Y, Wu H, et al. Therapeutic advances in the treatment of SLE. Int Immunopharmacol. 2019;72:218–223. doi: 10.1016/j.intimp.2019.03.010
   PubMed Web of Science ®Google Scholar
• Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5(5):e79. doi: 10.1038/cti.2016.26
   PubMedGoogle Scholar
• Mathias LM, Stohl W. Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opin Ther Targets. 2020;24(12):1283–1302. doi: 10.1080/14728222.2020.1832464
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):339–347. doi: 10.1038/nrrheum.2010.64
   PubMed Web of Science ®Google Scholar
• Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125–139. doi:10.1016/j.pharmthera.2013.09.004
   PubMed Web of Science ®Google Scholar
• Jin S, Yu C, Yu B. Changes of serum IL-6, IL-10 and TNF-α levels in patients with systemic lupus erythematosus and their clinical value. Am J Transl Res. 2021;13(4):2867–2874.
   PubMed Web of Science ®Google Scholar
• Talaat RM, Mohamed SF, Bassyouni IH, et al. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine. 2015;72(2):146–153. doi:10.1016/j.cyto.2014.12.027
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck J-P, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through Type I interferon and interleukin 6. Immunity. 2003;19(2):225–234. doi:10.1016/S1074-7613(03)00208-5
   PubMed Web of Science ®Google Scholar
• Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL- Fas lpr mice: the iL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37(1):60–70. doi:10.3899/jrheum.090194
   PubMed Web of Science ®Google Scholar
• Katkam SK, Rajasekhar L, Kumaraswami K, et al. Association of IL - 6 -174 G>C polymorphism with the risk of SLE among south Indians: evidence from case–control study and meta-analysis. Lupus. 2017;26:1491–1501. doi: 10.1177/0961203317711010
   PubMed Web of Science ®Google Scholar
• Richards HB, Satoh M, Shaw M, et al. Interleukin 6 dependence of Anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med. 1998;188(5):985–990. doi:10.1084/jem.188.5.985
   PubMed Web of Science ®Google Scholar
• Jung J-Y, Kim M-Y, Suh C-H, et al. Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review. Pediatr Rheumatol. 2018;16(1):79. doi:10.1186/s12969-018-0296-z
   PubMedGoogle Scholar
• Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865–1879. doi: 10.1007/s40265-017-0829-7
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa1613849
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–552. doi:10.1002/art.27221
   PubMed Web of Science ®Google Scholar
• Hirooka Y, Okuda S, Sugiyama M, et al. Case report: a rare case of elderly-onset adult-onset still’s disease in a patient with systemic lupus erythematosus. Front Immunol. 2022;13:822169. doi: 10.3389/fimmu.2022.822169
   PubMedGoogle Scholar
• De Matteis A, Sacco E, Celani C, et al. Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus. Pediatr Rheumatol. 2021;19(1):144. doi:10.1186/s12969-021-00635-w
   PubMed Web of Science ®Google Scholar
• Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–283. doi: 10.1038/nrg.2016.20
   PubMed Web of Science ®Google Scholar
• Yamamura S, Imai-Sumida M, Tanaka Y, et al. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75(3):467–484. doi:10.1007/s00018-017-2626-6
   PubMed Web of Science ®Google Scholar
• Liu X, Sun M, Nie F, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13(1):92. doi:10.1186/1476-4598-13-92
   PubMed Web of Science ®Google Scholar
• Imig J, Brunschweiger A, Brümmer A, et al. MiR-CLIP capture of a miRNA targetome uncovers a lincRNA H19–miR-106a interaction. Nat Chem Biol. 2015;11(2):107–114. doi:10.1038/nchembio.1713
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Wu H, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366–5383. doi:10.1093/nar/gkq285
   PubMed Web of Science ®Google Scholar
• Bond CS, Fox AH. Paraspeckles: nuclear bodies built on long noncoding RNA. J Cell Bio. 2009;186(5):637–644. doi: 10.1083/jcb.200906113
   PubMed Web of Science ®Google Scholar
• Wang Y, Hou L, Yuan X, et al. LncRNA NEAT1 targets fibroblast-like synoviocytes in rheumatoid arthritis via the miR-410-3p/YY1 axis. Front Immunol. 2020;11:1975. doi: 10.3389/fimmu.2020.01975
   PubMed Web of Science ®Google Scholar
• Zhang F, Wu L, Qian J, et al. Identification of the long noncoding RNA NEAT1 as a novel inflammatory regulator acting through MAPK pathway in human lupus. J Autoimmun. 2016;75:96–104. doi: 10.1016/j.jaut.2016.07.012
   PubMed Web of Science ®Google Scholar